Transgenic Parasites Stably Expressing Full-Length Plasmodium falciparum Circumsporozoite Protein as a Model for Vaccine Down-Selection in Mice Using Sterile Protection as an Endpoint

The Santa Lucia Strain of Plasmodium falciparum in Aotus Monkeys

(2018) William E. Collins et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Full-Length Plasmodium falciparum Circumsporozoite Protein Administered with Long-Chain Poly(I·C) or the Toll-Like Receptor 4 Agonist Glucopyranosyl Lipid Adjuvant-Stable Emulsion Elicits Potent Antibody and CD4+T Cell Immunity and Protection in Mice

(2012) Kathrin Kastenmüller et al.   INFECTION AND IMMUNITY

Roles of the Amino Terminal Region and Repeat Region of the Plasmodium berghei Circumsporozoite Protein in Parasite Infectivity

(2012) Cassandra Aldrich et al.   PLoS One

Protective Antibody and CD8+ T-Cell Responses to the Plasmodium falciparum Circumsporozoite Protein Induced by a Nanoparticle Vaccine

(2012) Stephen A. Kaba et al.   PLoS One

Unexpected fold in the circumsporozoite protein target of malaria vaccines

(2012) M. B. Doud et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Protective immunity to pre-erythrocytic stage malaria

(2011) Robert J. Schwenk et al.   TRENDS IN PARASITOLOGY

Randomized, Double‐Blind, Phase 2a Trial of Falciparum Malaria Vaccines RTS,S/AS01B and RTS,S/AS02A in Malaria‐Naive Adults: Safety, Efficacy, and Immunologic Associates of Protection

(2009) Kent E. Kester et al.   JOURNAL OF INFECTIOUS DISEASES

Development of the RTS,S/AS malaria candidate vaccine

(2009) Johan Vekemans et al.   VACCINE

The N-terminal domain of Plasmodium falciparum circumsporozoite protein represents a target of protective immunity

(2008) Silayuv E. Bongfen et al.   VACCINE